share_log

INVO Bioscience | 8-K: INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

INVO Bioscience | 8-K: INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

INVO Bioscience | 8-K:INVO公布了创纪录的2024年第二季度财务业绩,收入增长了481%,调整后的息税折旧摊销前利润增长了110万美元
美股SEC公告 ·  2024/08/14 13:14
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息